TY - JOUR AU - Minen, Mia Tova AU - Reichel, Julia Frederica AU - Pemmireddy, Pallavi AU - Loder, Elizabeth AU - Torous, John PY - 2020 DA - 2020/8/4 TI -神经精神流动健康试验特征:在ClinicalTrials.gov上注册的研究横断面分析JMIR Mhealth Uhealth SP - e16180 VL - 8 IS - 8 KW -智能手机KW -移动电话KW -应用程序KW -心理健康KW -调节KW -中风KW -偏头痛KW -重度抑郁症KW -阿尔茨海默病KW -焦虑症KW -酒精使用障碍KW -阿片类药物使用障碍KW -癫痫KW -精神分裂症AB -背景:移动医疗(mHealth)技术的发展速度比评估其有效性和有效性的科学发展速度要快。根据国际期刊医学编辑委员会(ICMJE)的指导方针，在研究开始之前，前瞻性地将患者分配到干预措施的临床试验应在数据库中注册。目的:本研究的目的是更好地了解截至2018年11月在ClinicalTrials.gov上注册的针对高负担神经精神疾病的智能手机移动健康试验，包括正在进行的研究的数量、类型和特征;任何结果变化的频率和时间;报告结果。方法:我们在ClinicalTrials.gov网站上进行了一次系统搜索，查找与移动健康相关的十大最致残的神经精神疾病和预先指定的术语。根据2016年世界卫生组织全球疾病负担研究，十大最致残的神经精神疾病是(1)中风，(2)偏头痛，(3)重度抑郁症，(4)阿尔茨海默病和其他痴呆症，(5)焦虑症，(6)酒精使用障碍，(7)阿片类药物使用障碍，(8)癫痫，(9)精神分裂症，(10)其他精神和物质使用障碍。没有日期、地点或状态限制。 Results: Our search identified 135 studies. A total of 28.9% (39/135) of studies evaluated interventions for major depressive disorder, 14.1% (19/135) of studies evaluated interventions for alcohol use disorders, 12.6% (17/135) of studies evaluated interventions for stroke, 11.1% (15/135) of studies evaluated interventions for schizophrenia, 8.1% (11/135) of studies evaluated interventions for anxiety disorders, 8.1% (11/135) of studies evaluated interventions for other mental and substance use disorders, 7.4% (10/135) of studies evaluated interventions for opioid use disorders, 3.7% (5/135) of studies evaluated interventions for Alzheimer disease or other dementias, 3.0% (4/135) of studies evaluated interventions for epilepsy, and 3.0% (4/135) of studies evaluated interventions for migraine. The studies were first registered in 2008; more than half of the studies were registered from 2016 to 2018. A total of 18.5% (25/135) of trials had results reported in some publicly accessible location. Across all the studies, the mean estimated enrollment (reported by the study) was 1078, although the median was only 100. In addition, across all the studies, the actual reported enrollment was lower, with a mean of 249 and a median of 80. Only about a quarter of the studies (35/135, 25.9%) were funded by the National Institutes of Health. Conclusions: Despite the increasing use of health-based technologies, this analysis of ClinicalTrials.gov suggests that only a few apps for high-burden neuropsychiatric conditions are being clinically evaluated in trials. SN - 2291-5222 UR - https://mhealth.www.mybigtv.com/2020/8/e16180 UR - https://doi.org/10.2196/16180 UR - http://www.ncbi.nlm.nih.gov/pubmed/32749230 DO - 10.2196/16180 ID - info:doi/10.2196/16180 ER -